Courtagen Life Sciences, Inc., a Woburn, Mass.-based commercial-stage, innovative molecular information company, closed $20m growth equity funding round.
Backers included original investors Harbor Light Capital and Adler & Co., and new investors Bunker Hill Capital, First Analysis, as well as other high net worth investors. In conjunction with the financing, Chuck Farkas, Partner at Bain & Co., and Tracy Marshbanks, Managing Director at First Analysis, will join Courtagen’s Board of Directors as a Board Member and Board Observer, respectively.
The company intends to use the funds for the commercialization efforts for its pediatric neurology DNA sequencing and molecular information assays.
Led by Brian McKernan, Chief Executive Officer, Courtagen converts genomic data into actionable clinical information for the diagnosis of critical pediatric neurological and metabolic disorders. Specifically, the company focuses on mitochondrial disorders, epilepsy, and intellectual disability, including autism spectrum disorders.